Educational content only. Sequence & Signal sells nothing and does not provide medical advice. Talk to a licensed clinician about anything that concerns your health.
Every brief is a reading guide to a body of evidence or a set of documents. Each one names its sources, states what the record establishes, and marks where it stops. None of them contains dosing, protocols, product comparisons, or sourcing information, and none ever will.
A Toronto laboratory had a working extract by 1922. Turning it into a medicine that behaved the same way twice took another sixty years, and that is where modern biologic standardization comes from.
A purity percentage answers one narrow question. Identity, sterility, and endotoxin content are three others, tested by different methods — and a document can look official while establishing almost nothing.
The cardiovascular and weight-outcome programmes were large, long, and precise about their endpoints. Reading them well means separating what was measured from what was later claimed about it.
The lists are an administrative mechanism with a nomination process, an advisory committee, and a public docket — not a safety endorsement. Understanding the difference explains most of the confusion around them.
Reviewers assess design, analysis, and whether the conclusions follow. They almost never see the raw data, cannot detect a fabricated dataset, and are not checking that the study was run as described.
The conventional cut-off is a rule of thumb, not a chemical boundary, and regulators, chemists, and marketers all draw it in different places. The word does a lot of work it was never built for.
A biomarker that tracks a disease is not automatically a biomarker that predicts benefit from treating it. The history of surrogate endpoints includes some of the most instructive failures in modern trial design.
Preprints are a legitimate and useful part of the record. They are also unreviewed, sometimes revised beyond recognition, and occasionally withdrawn — and none of that is visible in a screenshot.
Helen Adeyemi·In edit
How to use the library
Three buckets, every time
Whenever a brief names a compound or a compound class, it says which of three categories applies. We repeat the categories rather than assuming the reader remembers them, because the distinction is where most misreadings begin.
Classification we apply
Approved
An FDA-approved drug product with a specific approved indication, an approved label, and a manufacturer subject to inspection.
In trials
A compound currently under study in registered human clinical trials. Being in trials means a question is open, not that an answer exists.
Neither
A compound with no approval and no completed human trials supporting any therapeutic claim. Preclinical or animal data, where it exists, does not change this classification.
Briefs marked In edit are drafted and in fact-checking. We publish when checking is finished, not on a schedule.
The Weekly Read
Know when a brief lands.
Thursday mornings, a short annotated list of what published this week — and a note when something new appears in the library.
We store your address to send the newsletter and nothing else. See our privacy policy.